AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31672177 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (12-month DAPT followed by 12-month aspirin)
Number of subjects: 15991
Study 31672177 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 15991
Study 29196304 — intervention group
Group type: EXPERIMENTAL
Intervention: Early initiation of RRT (stage 2 AKI)
Number of subjects: 230
Study 29196304 — intervention group
Group type: COMPARATOR
Intervention: Delayed initiation of RRT (stage 3 AKI)
Number of subjects: 230
Study 29196304 — intervention group
Group type: EXPERIMENTAL
Intervention: Early initiation of RRT
Number of subjects: 230
Study 29196304 — intervention group
Group type: COMPARATOR
Intervention: Delayed initiation of RRT
Number of subjects: 230
Study 26864363 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 8089
Study 26864363 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant-supplemented group
Number of subjects: 8089
Study 24656221 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 96
Study 24656221 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 96
Study 21945867 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrained eaters who drank a milkshake
Number of subjects: 20
Study 21945867 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline restrained eaters
Number of subjects: 20
Study 21945867 — intervention group
Group type: COMPARATOR
Intervention: Unrestrained co-twins
Number of subjects: 20
Study 20568656 — intervention group
Group type: EXPERIMENTAL
Intervention: St. John's wort extract WS 5570 (600-1800 mg/day)
Number of subjects: 1661
Study 20568656 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine (20 or 40 mg/day)
Number of subjects: 1661
Study 20568656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1661
Study 17254329 — intervention group
Group type: EXPERIMENTAL
Intervention: Emulsified oil mixture
Number of subjects: 24
Study 17254329 — intervention group
Group type: COMPARATOR
Intervention: Oil mixture
Number of subjects: 24
Study 15580433 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxout implant
Number of subjects: 3
Study 15580433 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxout implant (intraoral placement)
Number of subjects: 3
Study 15580433 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxout implant (transnasal replacement)
Number of subjects: 3
Study 11821608 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic bipolar coagulation of uterine vessels (LBCUV) and laparoscopic supracervical amputation followed by trachelectomy
Number of subjects: 64
Study 11821608 — intervention group
Group type: COMPARATOR
Intervention: Hysterectomy without LBCUV
Number of subjects: 64
Study 10476242 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Number of subjects: 0
Study 10476242 — intervention group
Group type: COMPARATOR
Intervention: Low doses of interferon beta-1a administered once weekly
Number of subjects: 0
Study 10476242 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher, more frequent doses of interferon beta-1a
Number of subjects: 0
Study 7562390 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated exposure to sexually violent films
Number of subjects: 0
Study 7562390 — intervention group
Group type: COMPARATOR
Intervention: No exposure to sexually violent films (comparison group)
Number of subjects: 0
Study 2695566 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids and anti-thymocyte globulin (ATG) for 2-4 weeks and prednisone for 2 months
Number of subjects: 24
Study 2695566 — intervention group
Group type: COMPARATOR
Intervention: Untreated IDD patients
Number of subjects: 24
Study 2695566 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 24
Study 2695566 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids and ATG
Number of subjects: 24
Study 894798 — intervention group
Group type: EXPERIMENTAL
Intervention: Massive penicillin dosage (60 million units)
Number of subjects: 50
Study 894798 — intervention group
Group type: COMPARATOR
Intervention: Ticarcillin (200 mg. per kg.)
Number of subjects: 50
Study 31150976 — intervention group
Group type: COMPARATOR
Intervention: Placebo group with PFOA concentration > median (4.9 ng/mL)
Number of subjects: 888
Study 31150976 — intervention group
Group type: EXPERIMENTAL
Intervention: PFOA
Number of subjects: 888
Study 31150976 — intervention group
Group type: EXPERIMENTAL
Intervention: PFHxS
Number of subjects: 888
Study 31150976 — intervention group
Group type: EXPERIMENTAL
Intervention: PFNA
Number of subjects: 888
Study 28417914 — intervention group
Group type: COMPARATOR
Intervention: Above median serum 25(OH)D levels in the placebo arm
Number of subjects: 3377
Study 28417914 — intervention group
Group type: COMPARATOR
Intervention: Serum IGFBP‐3 levels
Number of subjects: 3377
Study 25348524 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2251052
Number of subjects: 14
Study 23410265 — intervention group
Group type: EXPERIMENTAL
Intervention: Melodies presented in the same or similar articulation format from study to test
Number of subjects: 0
Study 23410265 — intervention group
Group type: EXPERIMENTAL
Intervention: Melodies rated as perceptually dissimilar due to articulation mismatch
Number of subjects: 0
Study 23410265 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall proportion of articulation mismatch
Number of subjects: 0
Study 21884148 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:100,000 adrenaline
Number of subjects: 20
Study 21884148 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:200,000 adrenaline
Number of subjects: 20
Study 21884148 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 adrenaline
Number of subjects: 20
Study 21884148 — intervention group
Group type: EXPERIMENTAL
Intervention: Different clinical stages of dental procedures
Number of subjects: 20
Study 19483232 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of tranexamic acid
Number of subjects: 73
Study 19483232 — intervention group
Group type: COMPARATOR
Intervention: No tranexamic acid
Number of subjects: 73
Study 17267928 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavioural therapy with telephone support
Number of subjects: 57
Study 17267928 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 57
Study 15097769 — intervention group
Group type: COMPARATOR
Intervention: Three scans per examination
Number of subjects: 48
Study 15097769 — intervention group
Group type: EXPERIMENTAL
Intervention: Five scans per examination
Number of subjects: 48
Study 15097769 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven scans per examination
Number of subjects: 48
Study 11698314 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil 1 mg
Number of subjects: 270
Study 9135873 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV protease inhibitor saquinavir (SQV) in combination with zidovudine (ZDV)
Number of subjects: 86
Study 7520906 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (2, 6 mg/day)
Number of subjects: 2
Study 7520906 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (6, 10, 16 mg/day)
Number of subjects: 2
Study 7520906 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (20 mg/day)
Number of subjects: 2
Study 7520906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 7520906 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (10 mg/day)
Number of subjects: 2
Study 2544117 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled formoterol
Number of subjects: 9
Study 2544117 — intervention group
Group type: COMPARATOR
Intervention: Inhaled salbutamol
Number of subjects: 9
Study 2544117 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral formoterol
Number of subjects: 9
Study 2544117 — intervention group
Group type: COMPARATOR
Intervention: Oral salbutamol
Number of subjects: 9
Study 1092411 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent electrical calf muscle stimulation during surgery
Number of subjects: 3
Study 1092411 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin calcium 5000 IU every eight hours for six days
Number of subjects: 3
Study 1092411 — intervention group
Group type: COMPARATOR
Intervention: No specific prophylaxis
Number of subjects: 3
Study 29917096 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile mindfulness training with experience sampling (MMT-ES)
Number of subjects: 325
Study 29917096 — intervention group
Group type: COMPARATOR
Intervention: Experience sampling only (ES)
Number of subjects: 325
Study 29917096 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (MMT-ES and ES)
Number of subjects: 325
Study 31387868 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivotal Response Treatment Package (PRT‐P)
Number of subjects: 48
Study 31387868 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment group
Number of subjects: 48
Study 26951348 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates exercise training
Number of subjects: 45
Study 26951348 — intervention group
Group type: COMPARATOR
Intervention: Standardized physical therapy
Number of subjects: 45
Study 23332882 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5mg once daily
Number of subjects: 26
Study 23332882 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin 5mg twice daily
Number of subjects: 26
Study 23332882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 22150035 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination-therapy group (rifapentine 900 mg + isoniazid 900 mg for 3 months)
Number of subjects: 7731
Study 22150035 — intervention group
Group type: COMPARATOR
Intervention: Isoniazid-only group (isoniazid 300 mg for 9 months)
Number of subjects: 7731
Study 19458028 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Carbohydrate (HC) meal
Number of subjects: 27
Study 19458028 — intervention group
Group type: COMPARATOR
Intervention: High-Fat (HF) meal
Number of subjects: 27
Study 22184370 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 386 10 mg/kg QW plus paclitaxel
Number of subjects: 161
Study 22184370 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 386 3 mg/kg QW plus paclitaxel
Number of subjects: 161
Study 22184370 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus paclitaxel
Number of subjects: 161
Study 16006832 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga program
Number of subjects: 0
Study 16006832 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 12458361 — intervention group
Group type: EXPERIMENTAL
Intervention: Al-adjuvanted low-dose formulations (1.9 micro g HA/strain per dose)
Number of subjects: 0
Study 12458361 — intervention group
Group type: EXPERIMENTAL
Intervention: Al-adjuvanted low-dose formulations
Number of subjects: 0
Study 12458361 — intervention group
Group type: COMPARATOR
Intervention: Standard split virus vaccine (Fluarix)
Number of subjects: 0
Study 12458361 — intervention group
Group type: EXPERIMENTAL
Intervention: Al-adjuvanted whole virus formulations with reduced antigen content
Number of subjects: 0
Study 12458361 — intervention group
Group type: EXPERIMENTAL
Intervention: Al-adjuvanted whole virus vaccines with low HA content
Number of subjects: 0
Study 9593249 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 20)
Number of subjects: 82
Study 9593249 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical (n = 21)
Number of subjects: 82
Study 9593249 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical plus oral metronidazole (n = 20)
Number of subjects: 82
Study 9593249 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol preparation (n = 21)
Number of subjects: 82
Study 8553302 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone (BDP) 800 micrograms/day
Number of subjects: 12
Study 8553302 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone (BDP) 2000 micrograms/day
Number of subjects: 12
Study 8553302 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone (BDP) 1400 micrograms/day
Number of subjects: 12
Study 8553302 — intervention group
Group type: COMPARATOR
Intervention: Inhaled placebo
Number of subjects: 12
Study 2242972 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide (400 mg b.i.d., intramuscular injection, starting one day before surgery and continuing for seven postoperative days)
Number of subjects: 160
Study 2242972 — intervention group
Group type: COMPARATOR
Intervention: Calcium heparin (5000 IU t.i.d., subcutaneous injection, starting two hours before surgery and continuing for seven days)
Number of subjects: 160
Study 2242972 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide
Number of subjects: 160
Study 2242972 — intervention group
Group type: COMPARATOR
Intervention: Calcium heparin
Number of subjects: 160
Study 76165 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine therapy for 6 weeks
Number of subjects: 8
Study 76165 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cimetidine)
Number of subjects: 8
Study 11706341 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet-controlled
Number of subjects: 0
Study 11706341 — intervention group
Group type: COMPARATOR
Intervention: Control (no tourniquet)
Number of subjects: 0
Study 31254472 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 10854
Study 29046957 — intervention group
Group type: COMPARATOR
Intervention: Heller myotomy
Number of subjects: 41
Study 29046957 — intervention group
Group type: EXPERIMENTAL
Intervention: Heller myotomy with Dor fundoplication
Number of subjects: 41
Study 29046957 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 41
Study 26669989 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 24
Study 26669989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 26669989 — intervention group
Group type: COMPARATOR
Intervention: Subjective pain ratings
Number of subjects: 24
Study 26669989 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 24
Study 25131479 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lipid modulation (atorvastatin 40 mg every night before surgery, 80 mg 12 h before surgery, 40 mg 2 h before surgery, and 40 mg every night after surgery)
Number of subjects: 60
Study 25131479 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (atorvastatin 20 mg every night before surgery and after surgery)
Number of subjects: 60
Study 25131479 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lipid modulation
Number of subjects: 60
Study 25131479 — intervention group
Group type: COMPARATOR
Intervention: Conventional group
Number of subjects: 60
Study 22268852 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg/day
Number of subjects: 51
Study 22268852 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg/day
Number of subjects: 51
Study 22268852 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg/day
Number of subjects: 51
Study 22268852 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg/day plus Clopidogrel 75 mg/day
Number of subjects: 51
Study 22268852 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 51
Study 20528839 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpleural analgesia with a 20-ml loading dose of levo bupivacaine 0.5% followed by a continuous infusion of levobupivacaine 0.125%
Number of subjects: 50
Study 20528839 — intervention group
Group type: COMPARATOR
Intervention: Multimodal analgesia with intravenous morphine patient‐controlled analgesia
Number of subjects: 50
Study 20528839 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpleural analgesia
Number of subjects: 50
Study 17114188 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 200
Study 17114188 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by infliximab
Number of subjects: 200
Study 15890355 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine serum albumin (BSA) as an intrathoracic surgical sealant during pneumonectomy
Number of subjects: 143
Study 15890355 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 143
Study 12553485 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) + Lamivudine (3TC)
Number of subjects: 113
Study 12553485 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir (ABC) + Lamivudine (3TC)
Number of subjects: 113
Study 12553485 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir (NFV)
Number of subjects: 113
Study 12553485 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV)
Number of subjects: 113
Study 12553485 — intervention group
Group type: EXPERIMENTAL
Intervention: 3TC
Number of subjects: 113
Study 12553485 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) + Abacavir (ABC)
Number of subjects: 113
Study 12553485 — intervention group
Group type: EXPERIMENTAL
Intervention: 3TC + ABC
Number of subjects: 113
Study 10392107 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention (education about nutrition and parenting skills)
Number of subjects: 39
Study 7664901 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative hyperthermo-chemo-radiotherapy (HCR)
Number of subjects: 51
Study 7664901 — intervention group
Group type: COMPARATOR
Intervention: Pre-operative radiation therapy alone (R)
Number of subjects: 51
Study 2701039 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 120‐480 mg daily, mean dose 280 mg for 6‐9 weeks
Number of subjects: 40
Study 2701039 — intervention group
Group type: COMPARATOR
Intervention: Pindolol 10‐35 mg daily, mean dose 22 mg for 6‐9 weeks
Number of subjects: 40
Study 67468 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal administration of 200 units of antitetanus serum (A.T.S.) (horse)
Number of subjects: 322
Study 67468 — intervention group
Group type: COMPARATOR
Intervention: Control series (no intrathecal A.T.S.)
Number of subjects: 322
Study 67468 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal administration of 200 units A.T.S. (horse)
Number of subjects: 322
Study 31968307 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Fatigue (MF) - 60-min incongruent Stroop task
Number of subjects: 19
Study 31968307 — intervention group
Group type: COMPARATOR
Intervention: Control - 60 min of an emotionally neutral documentary
Number of subjects: 19
Study 30113523 — intervention group
Group type: EXPERIMENTAL
Intervention: ET-BFR (n = 10, 4 d·wk, 30-min cycling at 40% of V˙O2max)
Number of subjects: 30
Study 30113523 — intervention group
Group type: COMPARATOR
Intervention: RT (n = 10, 4 d·wk, 4 sets of 10 repetitions leg press at 70% of one repetition maximum with 60 s rest)
Number of subjects: 30
Study 30113523 — intervention group
Group type: COMPARATOR
Intervention: ET (n = 10, 4 d·wk, 30-min cycling at 70% of V˙O2max)
Number of subjects: 30
Study 28082016 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet computer training intervention (N=22 participants attended a weekly 2-hour class for 10 weeks)
Number of subjects: 48
Study 28082016 — intervention group
Group type: COMPARATOR
Intervention: Control group (N=21 participants)
Number of subjects: 48
Study 25585164 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally processed wheat bran
Number of subjects: 27
Study 25585164 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat aleurone
Number of subjects: 27
Study 25585164 — intervention group
Group type: EXPERIMENTAL
Intervention: Aleurone bread
Number of subjects: 27
Study 25585164 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 27
Study 23514124 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 160
Study 23514124 — intervention group
Group type: COMPARATOR
Intervention: Light therapy (LT)
Number of subjects: 160
Study 21503000 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg once daily (933 subjects)
Number of subjects: 1561
Study 21503000 — intervention group
Group type: COMPARATOR
Intervention: Placebo (628 subjects)
Number of subjects: 1561
Study 18512045 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural triggering and cycling-off
Number of subjects: 7
Study 18512045 — intervention group
Group type: COMPARATOR
Intervention: Pneumatic triggering and cycling-off
Number of subjects: 7
Study 16585287 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow's milk-elimination diet (n = 19)
Number of subjects: 40
Study 16585287 — intervention group
Group type: COMPARATOR
Intervention: Continue previous diet (n = 21)
Number of subjects: 40
Study 16585287 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 40
Study 12815302 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective endothelin receptor-A antagonist BQ-123 administered by the intracoronary route
Number of subjects: 0
Study 10577557 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine 2 microg/kg/min plus 120 ml/day of 0.9% saline
Number of subjects: 66
Study 10577557 — intervention group
Group type: COMPARATOR
Intervention: Saline alone
Number of subjects: 66
Study 8712126 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute catheterization, angioplasty, thrombolysis, or coronary bypass surgery (men)
Number of subjects: 1097
Study 8712126 — intervention group
Group type: COMPARATOR
Intervention: Hospital mortality (women)
Number of subjects: 1097
Study 8712126 — intervention group
Group type: COMPARATOR
Intervention: Older age, early evidence of hemodynamic instability, intraventricular conduction abnormality on ECG (predictors for hospital mortality)
Number of subjects: 1097
Study 2022160 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-soluble diclofenac
Number of subjects: 14
Study 2022160 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-release diclofenac
Number of subjects: 14
Study 2022160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 6756632 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime perioperatively only
Number of subjects: 360
Study 6756632 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime perioperatively plus postoperative doses every six hours for 24 hours
Number of subjects: 360
Study 6756632 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin perioperatively plus postoperative doses every six hours for 24 hours
Number of subjects: 360